Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Tenecteplase em Dose Baixa para Tratamento de Acidente Vascular Cerebral Isquémico Agudo em Pacientes Idosos (DATE-AGING)

1 de novembro de 2026 atualizado por: Zhenhua Zhou, Southwest Hospital, China

Eficácia e Segurança da Tenecteplase em Dose Baixa para o Tratamento do AVC Isquémico Agudo em Pacientes Idosos: Um Estudo Prospectivo, Multicêntrico, Randomizado e Controlado

The DATE-AGING study is a prospective, multicenter, randomized controlled trial investigating low-dose tenecteplase in elderly patients with acute ischemic stroke. Its primary objective is to evaluate the safety and efficacy of low-dose tenecteplase in elderly patients within 4.5 hours of acute ischemic stroke onset.

Visão geral do estudo

Tipo de estudo

Intervencional

Inscrição (Real)

806

Estágio

  • Fase 4

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

      • Anshan, China
        • Anshan Changda Hospital
      • Anyang, China
        • Anyang People's Hospital
      • Anyang, China
        • Huaxian People's Hospital of Henan
      • Baoshan, China
        • Baoshan People's Hospital
      • Bijie, China
        • People's Hospital of Zhijin County
      • Chongqing, China
        • Chongqing University Three Gorges Hospital
      • Chongqing, China
        • Chongqing University Jiangjin Hospital
      • Chongqing, China
        • Bishan Hospital
      • Chongqing, China
        • Chongqing Emergency Medical Center
      • Chongqing, China
        • Chongqing University Fuling Hospital
      • Chongqing, China
        • Dianjiang People's Hospital OF Chongqing
      • Chongqing, China
        • People's Hospital Of Xiushan County
      • Chongqing, China
        • The People's Hospital of Dazu Chongqing
      • Chongqing, China
        • The People's Hospital of HeChuan, Chongqing
      • Chongqing, China
        • The People's Hospital of Rongchang Chongqing
      • Chongqing, China
        • The People's Hospital of Tongnan District Chongqing City
      • Chongqing, China
        • The Seventh People's Hospital of Chongqing
      • Chongqing, China
        • Tongliang Hospital
      • Chongqing, China
        • Yunyang County People's Hospital
      • Dali, China
        • Dali Bai Autonomous Prefecture People's Hospital
      • Dazhou, China
        • Dazhou Central Hospital
      • Deyang, China
        • The People's Hospital of Zhongjiang
      • Guang’an, China
        • Guang an People's Hospital
      • Guiyang, China
        • Guizhou Provincial People's Hospital
      • Guiyang, China
        • The Second People's Hospital of Guiyang(Guiyang Jinyang Hospital)
      • Ha’erbin, China
        • The First Affiliated Hospital of Harbin Medical University
      • Hebi, China
        • Xunxian People's Hospital
      • Heyuan, China
        • Heyuan People's Hospital
      • Huanggang, China
        • Qichun People's Hosiptal
      • Jianyang, China
        • The People's Hospital Of Jianyang City
      • Laixi, China
        • Laixi People's Hospital
      • Leshan, China
        • People's Hospital of Leshan
      • Leshan, China
        • Leshan Geriatric Specialized Hospital
      • Luoyang, China
        • Luoyang Mengjin People's Hospital
      • Nanchong, China
        • Nanbu People's Hospital
      • Pujiang, China
        • Puyang People's Hospital
      • Pujiang, China
        • The People's Hospital of Nan Le Xian
      • Shangqiu, China
        • People's Hospital of Ningling County
      • Shangqiu, China
        • The First People's Hospital of Shangqiu
      • Shaoyang, China
        • The First People ' S Hospital of Shao Yang
      • Shijiazhuang, China
        • The People's Hospital of Gaocheng
      • Wuhan, China
        • Wuhan Puren Hospital
      • Xiangyang, China
        • Xiangyang NO.1 People's Hospital
      • Yibin, China
        • The second people's hospital of Yibin
      • Zhumadian, China
        • Zhumadian Central Hospital
      • Zhuzhou, China
        • Zhuzhou Central Hospital
      • Zigong, China
        • Zigong Third People's Hospital
      • Ziyang, China
        • Ziyang Central Hospital
    • Chongqing Municipality
      • Chongqing, Chongqing Municipality, China, 400038
        • Southwest Hospital, Chongqing, China
    • Heilongjiang
      • Harbin, Heilongjiang, China, 150200
        • Wuchang People's Hospital
    • Henan
      • Zhoukou, Henan, China, 466300
        • Shenqiu County People's Hospital

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

70 anos e mais velhos (Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  1. Age ≥ 70 years;
  2. Diagnosis of ischaemic stroke with a measurable neurological deficit on National Institutes of Health Stroke Scale (NIHSS) (1≤ NIHSS ≤25); if NIHSS <4, patients have to be with at least a measurable deficit on motor power (upper or lower limbs ≥1);
  3. Stroke symptoms should have been present for at least 30 minutes (min) without significant improvement prior to randomisation;
  4. Thrombolytic therapy can be initiated within 4.5 Hour(s) (h) of Acute ischaemic stroke (AIS) onset;
  5. Patients with premorbid modified Rankin Scale (mRS) 0 or 1;
  6. Informed consent from the patient or surrogate.

Exclusion Criteria:

  1. Imaging demonstrates multi-lobar infarction (hypodensity >1/3 cerebral hemisphere);

  2. Acute bleeding diathesis or allergy to tenecteplase, including but not limited to

    • Known genetic predisposition to bleeding or significant bleeding disorder at present or within the past 6 Month(s) (m)
    • Administration of heparin within the previous 48 h and activated partial thromboplastin time (aPTT) exceeding the upper limit of normal for laboratory measurement
    • Current use of vitamin K based oral anticoagulants (e.g. warfarin) and a prolonged prothrombin time (International normalised Ratio (INR) > 1.7 or Prothrombin time (PT)>15 seconds (s)) or current use of novel oral anticoagulants (i.e. dabigitran, rivaroxiban, or apixiban) with prolongation of activated partial thromboplastin time (aPTT) and/or PT above the upper limit of the local laboratory reference range
    • Platelet count of below 100×10^9/ L
    • Any history of central nervous system damage (i.e. neoplasm, aneurysm, intracranial or spinal surgery)
    • Recent traumatic external heart massage or recent puncture of a non-compressive blood-vessel (e.g. subclavian or jugular vein puncture) , within the past 10 days
    • Known history of suspected intracranial haemorrhage or suspected subarachnoid haemorrhage from aneurysm
    • Neoplasm with increased haemorrhagic risk
    • Documented ulcerative gastrointestinal disease during the last 3 months, oesophageal varices, arterial aneurysm, or arterial/venous malformations
    • History of significant trauma or major surgery within the past 3 months.
    • Any known disorder associated with a significant increased risk of bleeding
  3. Intracranial hemorrhage (including parenchymal hemorrhage, intraventricular hemorrhage, subarachnoid hemorrhage, subdural/extradural hematoma, etc.);

  4. Blood glucose <2.8 mmol/L or >22.22 mmol/L;

  5. After active antihypertensive treatment, hypertension is still not under control: systolic blood pressure ≥180 mmHg, or diastolic blood pressure ≥100 mmHg;

  6. Seizure at stroke onset;

  7. Concurrent malignancy or severe systemic disease with an anticipated survival of less than 90 days;

  8. Participation in other clinical trials within 3 months prior to screening;

  9. Unsuitability or participation in this study as judged by the Investigator may result in subjects being exposed to greater risk.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Solteiro

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Low-Dose Tenecteplase

0.175mg/kg tenecteplase

Subjects will be randomized to low-dose group or standard-dose group in a 1:1 ratio. Patients in the low-dose group received tenecteplase (0.175 mg/kg) for intravenous thrombolysis. The upper dose limit is set to 17.5 mg/patient.

Comparador Ativo: Standard-Dose Tenecteplase

0.25mg/kg tenecteplase

Subjects will be randomized to low-dose group or standard-dose group in a 1:1 ratio. Patients in the standard-dose group received tenecteplase (0.25 mg/kg) for intravenous thrombolysis. The upper dose limit is set to 25 mg/patient.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Percentage of Participants With Modified Rankin Scale (mRS) Score of 0 or 1
Prazo: At Day 90±7 days

Modified Rankin Scale (mRS) is a standardized measure that describes the extent of disability after a stroke. The mRS is a single item scale. It increases from 0 (no symptoms at all) to 6 (death).

At Day 90±7 days

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Percentage of participants with major neurological improvement (National Institutes of Health Stroke Scale (NIHSS) score of 0 or improvement of at least 4 points compared with baseline)
Prazo: At 24 hours

National Institutes of Health Stroke Scale (NIHSS) is a 11-item neurologic examination stroke scale used to evaluate the effect of acute cerebral infarction on the levels of consciousness, language, neglect, visual-field loss, extraocular movement, motor strength, ataxia, dysarthria, and sensory loss. A trained observer rates the patent's ability to answer questions and perform activities. Ratings for each item are scored with 3 to 6 grades with 0 as normal, and there is an allowance for untestable items.Total NIHSS score (0-42) = sum of 11 individual item scores, higher total scores meaning more severe deficits.

At 24 hours
Percentage of Participants With Modified Rankin Scale (mRS) Score of 0-2
Prazo: At Day 90±7 days

Modified Rankin Scale (mRS) is a standardized measure that describes the extent of disability after a stroke. The mRS is a single item scale. It increases from 0 (no symptoms at all) to 6 (death).

At Day 90±7 days
Distribution of Modified Rankin Scale (mRS)
Prazo: At Day 90±7 days

Modified Rankin Scale (mRS) is a standardized measure that describes the extent of disability after a stroke. The mRS is a single item scale. It increases from 0 (no symptoms at all) to 6 (death).

At Day 90±7 days
Percentage of Participants With Barthel Index Score ≥95
Prazo: up to 90 days

The Barthel Index is an ordinal scale used to measure performance in activities of daily living (ADL). The Barthel Index consists of 10 items. The total score of the Barthel Index ranges from 0 to 100, and higher scores indicate better outcome.

up to 90 days
EQ-5D-5L score
Prazo: At Day 90±7 days

Health-related quality of life (the score on the EuroQol Group 5-Dimension 5-Level [EQ-5D-5L] questionnaire, range, -0.39 to 1, with higher scores indicating better quality of life)

At Day 90±7 days
Percentage of Participants With Symptomatic Intracerebral Haemorrhage (sICH)
Prazo: up to 36 hours

sICH via criteria adapted from the European Cooperative Acute Stroke Study (ECASS III), defined as any apparent extravascular blood in the brain or within the cranium that is associated with clinical deterioration defined by an NIHSS score increase of four points or more from baseline.

up to 36 hours
All-cause mortality
Prazo: up to 90 days

All-cause mortality at 90 days

up to 90 days
Percentage of Participants With Modified Rankin Scale (mRS) Score of 5 or 6
Prazo: At Day 90±7 days

Modified Rankin Scale (mRS) is a standardized measure that describes the extent of disability after a stroke. The mRS is a single item scale. It increases from 0 (no symptoms at all) to 6 (death).

At Day 90±7 days

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

19 de dezembro de 2025

Conclusão Primária (Real)

1 de novembro de 2026

Conclusão do estudo (Real)

1 de novembro de 2026

Datas de inscrição no estudo

Enviado pela primeira vez

21 de novembro de 2025

Enviado pela primeira vez que atendeu aos critérios de CQ

7 de dezembro de 2025

Primeira postagem (Real)

19 de dezembro de 2025

Atualizações de registro de estudo

Última Atualização Postada (Real)

3 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

1 de novembro de 2026

Última verificação

1 de novembro de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • 2025IITDA10

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

SIM

Tipo de informação de suporte de compartilhamento de IPD

  • PROTOCOLO DE ESTUDO
  • SEIVA
  • CSR

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever